GLPG - Galapagos NV
NASDAQ
->
Healthcare
->
Biotechnology
Mechelen,
Belgium
Type: Equity
GLPG price evolution
GLPG
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $52.33 | |||
| Short term investments | ||||
| Net receivables | $101.54 | $92.05 | $65.89 | |
| Inventory | $63.36 | $80.56 | $73.98 | |
| Total current assets | $3665.19 | $3786.47 | $3861.59 | |
| Long term investments | ||||
| Property, plant & equipment | $128.49 | $125.06 | $126.32 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $4290.37 | $4361.38 | $4357.4 | |
| Current liabilities | ||||
| Accounts payable | $128.31 | $145.55 | $135.2 | |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $364.78 | $382.21 | $428.22 | |
| Long term debt | $6.75 | $3.84 | $4.94 | |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $1380.07 | $1466.37 | $1561.83 | |
| Shareholders' equity | ||||
| Retained earnings | -$123.53 | -$138.61 | -$234.16 | |
| Other shareholder equity | $2.9 | $2.69 | -$1.2 | |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $71.8 | $458.12 | $2233.37 | $2135.19 |
| Short term investments | $2469.81 | |||
| Net receivables | $65.66 | $66.56 | $128.16 | $173.4 |
| Inventory | $73.98 | $52.92 | $20.57 | $0.35 |
| Total current assets | $3861.59 | $4236.85 | $4861.85 | $5369.35 |
| Long term investments | $8.95 | |||
| Property, plant & equipment | $126.32 | $154.25 | $137.51 | $103.38 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $397.96 | |||
| Total investments | ||||
| Total assets | $4357.4 | $4734.35 | $5193.16 | $5717.73 |
| Current liabilities | ||||
| Accounts payable | $134.65 | $148.68 | $137.42 | $171.32 |
| Deferred revenue | $506.22 | |||
| Short long term debt | ||||
| Total current liabilities | $428.22 | $522.54 | $566.47 | $635.27 |
| Long term debt | $4.94 | $14.69 | $19.66 | $23.04 |
| Total noncurrent liabilities | $2755.34 | |||
| Total debt | ||||
| Total liabilities | $1561.83 | $2208.32 | $2549.8 | $3047.38 |
| Shareholders' equity | ||||
| Retained earnings | -$234.16 | -$501.54 | -$367.2 | -$334.7 |
| Other shareholder equity | -$1.2 | -$1.59 | -$11.9 | -$76.6 |
| Total shareholder equity | $2643.36 | $2670.36 | ||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $59.85 | $85.12 | $71.82 | $287 |
| Cost of revenue | ||||
| Gross Profit | $59.83 | $68.57 | $69.27 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $114.13 | $106.75 | $102.4 | $375.26 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.57 | -$0.57 | -$0.57 | $9.61 |
| Interest expense | $5.16 | $42.27 | $56.07 | $93.89 |
| Net income | ||||
| Net income | -$50.43 | $8.98 | $90.22 | $211.7 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $287 | $552.13 | $484.85 | $530.26 |
| Cost of revenue | $493.34 | $523.67 | ||
| Gross Profit | $540.05 | -$8.49 | $6.59 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $210.85 | $185.22 | ||
| Total operating expenses | $375.26 | $780.87 | $650.44 | $708.89 |
| Operating income | -$165.6 | -$178.63 | ||
| Income from continuing operations | ||||
| EBIT | -$165.6 | -$178.63 | ||
| Income tax expense | $9.61 | $2.84 | $2.42 | $1.23 |
| Interest expense | $93.89 | $62.62 | -$8.8 | -$9.39 |
| Net income | ||||
| Net income | $211.7 | -$217.99 | -$103.23 | -$305.44 |
| Income (for common shares) | -$103.23 | -$305.44 | ||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $152.24 | $95.68 | $29.66 | $71.19 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$3.32 | -$2.23 | -$1.17 | -$5 |
| Effect of exchange rate | $0.45 | $0.94 | $0.5 | -$1.52 |
| Change in cash and equivalents | -$111.29 | -$94.48 | -$93.44 | -$341.31 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | -$103.23 | -$305.44 | ||
| Operating activities | ||||
| Depreciation | $14.84 | |||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$503.83 | -$427.34 | ||
| Investing activities | ||||
| Capital expenditures | -$54.2 | -$42.52 | ||
| Investments | $570.41 | $845.05 | ||
| Total cash flows from investing | $71.19 | -$1245.51 | $541.24 | $757.29 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$7.19 | -$6.25 | ||
| Total cash flows from financing | -$5 | -$1.49 | -$3.88 | $22.04 |
| Effect of exchange rate | -$1.52 | $22.29 | $56.76 | -$70.54 |
| Change in cash and equivalents | -$341.31 | -$1725.25 | $90.3 | $281.45 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $503.79M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $260.47M |
| Revenue Q/Q | -56.10% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |